Viewing Study NCT05248659

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:06 PM
Ignite Modification Date: 2026-01-24 @ 8:38 PM
Study NCT ID: NCT05248659
Status: ENROLLING_BY_INVITATION
Last Update Posted: 2024-12-09
First Post: 2022-02-18
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Immunoglobulin A Nephropathy View
Keywords:

Keywords

Keyword Brief Keyword Text View
None IgAN View
None VIS649 View
None Sibeprenlimab View